Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Papillomavirus Infections 2Neoplasms 2Liver Neoplasms 2Liver Diseases 2Virus Diseases 1Stomach Neoplasms 1Rheumatic Diseases 1Primary Graft Dysfunction 1Liver Failure, Acute 1Liver Failure 1Head and Neck Neoplasms 1HIV Infections 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

Cisplatin 76Radiotherapy 44pembrolizumab 39Cetuximab 38Paclitaxel 34Carboplatin 33Docetaxel 30Fluorouracil 25Radiotherapy, Intensity-Modulated 22Nivolumab 18Drug Therapy 14Radiation 12Erlotinib Hydrochloride 9cemiplimab 8Magnetic Resonance Spectroscopy 8130-nm albumin-bound paclitaxel 8durvalumab 7atezolizumab 7Cyclophosphamide 7Afatinib 7Surgical Procedures, Operative 6Panitumumab 6Leucovorin 6Chemoradiotherapy 6fludarabine 5aldesleukin 5Radiosurgery 5Oxaliplatin 5Methotrexate 5Gemcitabine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Squamous Cell × halofantrine × Clear all
NCT00490061 2017-03-06

Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy

Stanford University

Phase 2 Terminated
17 enrolled 7 charts
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡